
Azenta, Inc.: stock overview
Price
$45.65
November 13, 2026Market cap $2.1B
What Ploutos Investor adds for Azenta
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from FY2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has risen 49% since Aug 6, 2026, when the 10-Q these figures come from was filed ($30.74 then, $45.65 on Nov 13, 2026). The figures date from before that move.10-Q
- The latest annual figures the company filed are for 2025, more than a year ago. Newer ones may be late.
In short
Azenta had revenue of $614M over the last 12 months and a net loss of $123M. Revenue grew by 8.9% a year on average over the last 5 years. It holds more cash than debt, by $529M. It pays no dividend.
From its SEC filings (latest fiscal year to September 30, 2025) and the price of November 13, 2026.
Its SEC filings- Market cap
- $2.1B
- 45.99M shares
- P/E
- –
- Revenue, 12 months
- $614M
- +8.9% a year over 5 years
- Net margin
- -20.0%
- FY2025: -9.4%, above 15% of its industry
Worth knowing
What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.
3 fiscal years in figures
Each fiscal year's figures as the company filed them, and the share price at its end.
+3.8% a year over 2 years
Fiscal years in figures
AZTA's revenue, profit, cash flow and dividend with each year-end price, from FY2009 to FY2022, 14 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Key figures
The company's current figures in five groups. Each term is explained behind its ⓘ.
Valuation
- Market cap 3-year median: $2.2B
- $2.1B
- Enterprise value
- $1.6B
- P/E
- –
- EV / EBIT
- –
- EV / Revenue
- 2.6
- P/B 3-year median: 1.1
- 1.4
- FCF yield 3-year median: 0.6%
- 0.5%
- Earnings yield 3-year median: -4.2%
- –
Profitability
- Gross margin
- 44.1%
- Operating margin
- -28.6%
- Net margin 3-year median: -9.4%
- -20.0%
- ROIC
- -8.5%
- ROIC, 5-year average
- -1.6%
- ROE
- -7.5%
Growth
- Revenue, yearly change
- +3.6%
- EPS, yearly change
- –
- FCF, yearly change
- +210.3%
- Revenue, average a year
- +8.9%
The yearly change compares FY2025 with FY2024.
Balance sheet
- Cash
- $529M
- Total debt
- $54M
- Of which operating leases
- $54M
- Net cash
- $529M
- Net debt / EBITDA
- –
- Interest cover
- –
- Current ratio
- 2.50
Balance sheet of June 30, 2026.
Returns to shareholders
- Dividend yield
- 0.00%
- Buybacks
- –
- Total returned
- 0.00%
- Shares, yearly change
- +0.9%
Against its industry
Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 35).
Gross margin
45.5%
Above 77% of the 115 companies in its industry, and 64% of all.
Operating margin
-4.5%
Above 21% of the 138 companies in its industry, and 26% of all.
Net margin
-9.4%
Above 15% of the 147 companies in its industry, and 19% of all.
ROE
-3.3%
Above 19% of the 136 companies in its industry, and 25% of all.
ROA
-2.7%
Above 20% of the 146 companies in its industry, and 25% of all.
Revenue growth
3.6%
Above 41% of the 144 companies in its industry, and 40% of all.
From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.
The company at the SEC
How it is registered and when its fiscal year ends.
- Name at the SEC
- Azenta, Inc.
- CIK
- 933974
- Exchange
- NASDAQ
- Industry (SIC)
- 3559 · Special Industry Machinery, NEC
- Fiscal year ends
- September 30
- Latest annual report
- September 30, 2025
- Reporting currency
- USD
- Shares
- 45.99M
Other companies: Healthcare
The largest companies of the same sector, each with its own page.
- LLYEli Lilly and Company+0,00%Compare with AZTA
- JNJJohnson & Johnson+0,00%Compare with AZTA
- ABBVAbbVie+0,00%Compare with AZTA
- UNHUnitedHealth+0,00%Compare with AZTA
- MRKMerck & Company+0,00%Compare with AZTA
- AMGNAmgen+0,00%Compare with AZTA
- TMOThermo Fisher Scientific+0,00%Compare with AZTA
- ABTAbbott Laboratories+0,00%Compare with AZTA
The full analysis
What do Azenta's filings show?
These are Azenta's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
What is AZTA's market cap?
Azenta, Inc.'s market cap is $2.1B, at a price of $45.65 on November 13, 2026 and 45.99M shares.
How much revenue does AZTA have?
Azenta had revenue of $614M over the last 12 months. Over the last 5 years it changed by +8.9% a year on average.
Does AZTA pay a dividend?
No. Azenta paid no regular dividend over the last 12 months.
Where do the figures come from?
From Azenta, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.